Lipscomb University is a private, coeducational, liberal arts university in Nashville, Tennessee, United States. It is affiliated with the Churches of Christ. The campus is located in the Green Hills neighborhood of Nashville between Belmont Boulevard to the west and Granny White Pike on the east. Student enrollment for the fall 2013 semester is 4,593 which includes 2,897 undergraduate students and 1,696 graduate students. It also maintains a location in the Cool Springs area of Williamson County called "Spark." Wikipedia.
Gross B.,Lipscomb University
Journal of Pharmacy Practice | Year: 2013
This review presents clinical pearls for initiating liraglutide (Victoza®, Novo Nordisk Inc) therapy for the management of type 2 diabetes and selecting patients who will benefit from liraglutide therapy. Liraglutide, a once-daily glucagon-like peptide 1 receptor agonist, is Food and Drug Administration approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Liraglutide is effective for reducing hemoglobin A1c levels by 0.8% to 1.5% in patients with type 2 diabetes as monotherapy or in combination with other diabetic medications (such as metformin, sulfonylureas, rosiglitazone, or basal insulin) when compared with placebo and these other diabetic medications, including exenatide. Overweight or obese patients with type 2 diabetes or those with insulin resistance are good candidates for liraglutide therapy because liraglutide use is associated with weight loss (about 2%-4% of initial body weight) and improved β-cell function. The incidence of hypoglycemia with liraglutide is low; therefore, liraglutide would be a safe therapy choice for patients at risk or with a history of symptomatic or severe hypoglycemia. Nausea seems to be the most problematic adverse effect associated with liraglutide therapy, but it is usually transient and is minimized with dose titration. © The Author(s) 2012.
Kennedy S.E.,Lipscomb University
Information and Computer Security | Year: 2016
Purpose - Through the use of effective training techniques and exercises, employees and users can be educated on how to make safe information security decisions. It is critical to the success of a total information security program that users are trained properly as they are a major layer of defense against malicious intent. The current methods of training people about information security are failing, and the number of user-related breaches increases every year. Design/methodology/approach - By researching and observing current methods and comparing other fields of study, this paper describes the best methodology for modifying user behavior as it pertains to information security. Findings - Through effective training practices, user negligence can be mitigated and controlled, and the information security program can be better practiced throughout entire organizations. Originality/value - By using an effective training method to teach employees about information security, employees become an invaluable part of a company's overall information security strategy. By using this method, employees are no longer the weak link in information security. © Emerald Group Publishing Limited.
Phipps L.R.,Lipscomb University
Journal of Chemical Education | Year: 2013
An introductory, nonscience-majors chemistry course was converted to a Web-based course. The differences in student populations, teaching strategies, laboratory methods, and learning outcomes are described. Practical information is also given on the use of software and other online technology to implement course conversion. © 2013 The American Chemical Society and Division of Chemical Education, Inc.
Cole D.A.,Vanderbilt University |
Maxwell M.A.,Vanderbilt University |
Dukewich T.L.,Vanderbilt University |
Yosick R.,Lipscomb University
Journal of Clinical Child and Adolescent Psychology | Year: 2010
The goal was to examine the relation of covert/relational and overt/physical targeted peer victimization (TPV) to each other, to positive and negative self-cognitions, and to symptoms of depression. In a sample of elementary and middle school children, TPV was assessed by self-report, peer-nomination, and parent report in a multitrait-multimethod study. Positive and negative self-cognitions and depressive symptoms were assessed by self-report. Confirmatory factor analytic results support the convergent and discriminant validity of these two types of TPV. Both kinds of TPV were significantly related to positive and negative self-cognitions as well as self-reported depressive symptoms; however, structural equation modeling revealed that the effects of covert/relational TPV accounted for the effects of overt/physical TPV. In exploratory analyses, positive and negative self-cognitions explained the relation between TPV and depressive symptoms. © Taylor & Francis Group, LLC.
Richard Thompson J.,Lipscomb University
World Journal of Gastroenterology | Year: 2014
Until recently the traditional treatment for hepatitis C infection included pegylated interferon and ribavirin combination therapy. The sustained virological response (SVR) seen with this combination is poor and requires lengthy treatment to achieve. Additionally, significant side effects and numerous contraindications prevented many patients from being successfully treated with this therapy. In 2011, two new protease inhibitors, telaprevir and boceprevir, were approved for use with pegylated interferon and ribavirin in the United States by the United States Food and Drug Administration. These agents have significantly improved SVR rates; however significant problems with toxicity remain including severe skin rash and neutropenia. There are a wide range of compounds in late stage development for the future treatment of hepatitis C that exploit many different mechanisms of viral inhibition. Some of these compounds include additional protease inhibitors, like telaprevir and boceprevir, as well as inhibitors of other nonstructural proteins in the viral genome such as NS5A and NS5B, and compounds that target host proteins within the virus. Some of these agents are being developed for oral administration once daily and various combinations are being assessed for use without the need for pegylated interferon and ribavirin. This paper reviews agents in late phase development that may be commercially available within 1-2 years. © 2014 Baishideng Publishing Group Inc. All rights reserved.